NCCN Guidelines Version 4.2024
- Ductal Carcinoma in situ (DCIS)
- Invasive Breast Cancer
- Special consideration: Breast Cancer During Pregnancy
- Special consideration: Inflammatory Breast Cancer
- Special consideration: Paget Disease
- Special consideration: Phyllodes Tumor
Basic Resources (English) Version 4.2022
Core Resources (English) Version 4.2022
Enhanced Resources (English) Version 4.2022
Invasive Breast Cancer-English Version 2024
Metastatic Breast Cancer-English Version 2024
Ductal Carcinoma In Situ-English Version 2024
Inflammatory Breast Cancer-English Version 2023
Ductal Carcinoma In Situ-Spanish Version 2023
Metastatic Breast Cancer-Spanish Version 2023
Invasive Breast Cancer-Spanish Version 2023
Inflammatory Breast Cancer-Spanish Version 2023
Continuing Education
NCCN Guidelines® Insights - Breast Cancer Screening and Diagnosis, Version 1.2023
Neoadjuvant/Adjuvant Treatment for Breast Cancer with SABCS Updates
Advances in the Management of Metastatic Breast Cancer with SABCS Updates
Issues with Sexuality and Sexual Function in Patients with Breast Cancer
Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
NCCN Pharmacy Updates: Novel Therapies for Treating ESR1 and RET-Fusion Mutations in Breast Cancer
Translations
Arabic Version 4.2023
Bengali/Bangla Version 4.2023
Chinese Version 4.2022
French Version 8.2021
Hindi Version 4.2023
Italian Version 2.2022
Spanish Version 2.2022
Ukrainian Version 2.2022
Adaptations
English (Middle East & North Africa) Version 2.2023
English (European/Poland) Version 4.2023
Harmonized
English (Africa) Version 3.2024